Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review

The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB). The World Health Organization, based on lack of evidence, recommends their use under specific conditions and not in combination. No systematic...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of molecular sciences Vol. 18; no. 2; p. 341
Main Authors:	Migliori, Giovanni, Pontali, Emanuele, Sotgiu, Giovanni, Centis, Rosella, D’Ambrosio, Lia, Tiberi, Simon, Tadolini, Marina, Esposito, Susanna
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 07.02.2017 MDPI
Subjects:	Antitubercular Agents - therapeutic use Diarylquinolines - administration & dosage Diarylquinolines - adverse effects Diarylquinolines - therapeutic use Drug resistance Drug Therapy, Combination Extensively Drug-Resistant Tuberculosis - diagnosis Extensively Drug-Resistant Tuberculosis - drug therapy Extensively Drug-Resistant Tuberculosis - epidemiology Extensively Drug-Resistant Tuberculosis - microbiology Humans Multidrug resistant organisms Mycobacterium Nitroimidazoles - administration & dosage Nitroimidazoles - adverse effects Nitroimidazoles - therapeutic use Oxazoles - administration & dosage Oxazoles - adverse effects Oxazoles - therapeutic use Review Studies Treatment Outcome Tuberculosis Tuberculosis, Multidrug-Resistant - diagnosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - epidemiology Tuberculosis, Multidrug-Resistant - microbiology effectiveness safety tolerability MDR-TB delamanid XDR-TB bedaquiline
ISSN:	1422-0067, 1661-6596, 1422-0067
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!